Oriental Culture's 15min chart sees MACD Death Cross and KDJ Death Cross.

As per the 15-minute chart of Oriental Culture, the MACD and KDJ indicators have recently triggered death crosses, occurring on September 11, 2025 at 16:00. This technical analysis suggests that the stock price has the potential to continue declining, as the momentum of the stock price is shifting in a downward direction, which may lead to further decreases in value.

Modular Medical Inc. (NASDAQ: MODD) has seen a significant shift in its stock price dynamics following recent technical indicators. On September 11, 2025, at 16:00, the MACD and KDJ indicators for Oriental Culture triggered death crosses. This technical analysis suggests a potential downward trend in the stock price, as the momentum has shifted in a negative direction Modular Med Inc Stock Price, News & Analysis^[1].

The death cross, a technical indicator, occurs when the MACD line crosses below the signal line, indicating a bearish signal. Similarly, the KDJ indicator, which measures market momentum, also crossed below its signal line, reinforcing the bearish trend. These indicators are widely used by investors and traders to gauge the strength of a stock's trend and potential reversals.

The recent developments at Modular Medical, including the completion of clinical studies for its MODD1 pump and the announcement of its Pivot patch pump, have been promising. However, the technical indicators suggest that investors should be cautious about the stock's current trajectory.

Modular Medical's focus on user-friendly and affordable insulin delivery technology has positioned it as a leader in the diabetes care market. The company's FDA-cleared patch pump is designed specifically for the adult "almost-pumpers" market, representing a significant opportunity. Despite these advancements, the recent technical indicators warrant a closer examination of the stock's performance.

Investors should monitor the stock closely for any signs of a potential recovery or further decline. The upcoming FDA clearance of the Pivot pump in October 2025 and the planned product launch in Q1 2026 could provide additional insights into the company's future prospects.